About Vir Biotechnology, Inc.
https://www.vir.bioVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
CEO
Marianne De Backer
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 165
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
SB INVESTMENT ADVISERS (UK) LTD
Shares:16.68M
Value:$113.79M
BLACKROCK INC.
Shares:16.43M
Value:$112.08M
BLACKROCK, INC.
Shares:15.97M
Value:$108.9M
Summary
Showing Top 3 of 248
About Vir Biotechnology, Inc.
https://www.vir.bioVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $240K ▼ | $22.23M ▲ | $-163.14M ▼ | -67.98K% ▼ | $-1.17 ▼ | $-159.97M ▼ |
| Q2-2025 | $1.21M ▼ | $22.11M ▼ | $-110.96M ▲ | -9.14K% ▼ | $-0.8 ▲ | $-115.67M ▲ |
| Q1-2025 | $3.03M ▼ | $24.96M ▼ | $-120.97M ▼ | -3.99K% ▼ | $-0.88 ▼ | $-135.66M ▼ |
| Q4-2024 | $12.37M ▲ | $40.73M ▲ | $-104.59M ▲ | -845.23% ▲ | $-0.76 ▲ | $-100.23M ▲ |
| Q3-2024 | $2.38M | $38.46M | $-213.72M | -8.98K% | $-1.56 | $-215.7M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $506.51M ▼ | $1.02B ▼ | $223.35M ▼ | $796.1M ▼ |
| Q2-2025 | $606.02M ▼ | $1.19B ▼ | $245.06M ▼ | $947.47M ▼ |
| Q1-2025 | $801.66M ▼ | $1.31B ▼ | $263.91M ▲ | $1.04B ▼ |
| Q4-2024 | $905.35M ▼ | $1.4B ▼ | $248.43M ▼ | $1.15B ▼ |
| Q3-2024 | $914.47M | $1.5B | $257.63M | $1.24B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-163.14M ▼ | $-167.57M ▼ | $40.45M ▼ | $102K ▼ | $-127.02M ▼ | $-167.89M ▼ |
| Q2-2025 | $-110.96M ▲ | $-120.22M ▼ | $56.46M ▼ | $2.05M ▲ | $-61.72M ▼ | $-122.76M ▼ |
| Q1-2025 | $-120.97M ▼ | $-78.12M ▲ | $126.82M ▼ | $598K ▼ | $49.3M ▼ | $-79.75M ▲ |
| Q4-2024 | $-104.59M ▲ | $-87.64M ▲ | $140.74M ▲ | $1.26M ▲ | $54.37M ▲ | $-90.04M ▲ |
| Q3-2024 | $-213.72M | $-171.48M | $118.6M | $31K | $-52.86M | $-173.84M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenue | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Contract Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Marianne De Backer
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 165
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
SB INVESTMENT ADVISERS (UK) LTD
Shares:16.68M
Value:$113.79M
BLACKROCK INC.
Shares:16.43M
Value:$112.08M
BLACKROCK, INC.
Shares:15.97M
Value:$108.9M
Summary
Showing Top 3 of 248